

This primary care pathway was co-developed by primary and specialty care and includes input from multidisciplinary teams. It is intended to be used in conjunction with specialty advice services, when required, to support care within the medical home. Wide adoption of primary care pathways can facilitate timely, evidence-based support to physicians and their teams who care for patients with common low-risk GI conditions and improve appropriate access to specialty care, when needed. To learn more about primary care pathways, check out this short video.

# CHRONIC DIARRHEA PATHWAY PRIMER

- Chronic diarrhea is defined as 3 or more loose or watery stools/day (Type 6-7 on the <u>Bristol Stool Chart</u>) often associated with an increase in frequency, but not always, and persisting for more than 4 weeks in duration. Symptoms can also include an urgent need to pass stool and occasional incontinence, with significant impact on the patient's quality of life.
- This clinical pathway focuses only on the investigation and management of chronic diarrhea.
  - Acute diarrhea is defined as 30 days or less. In Canada, acute diarrhea is most often infectious and often requires only self-limited symptom management.
- Chronic diarrhea is common gastrointestinal disorder, affecting approximately 3-5% of the general population.<sup>1</sup>
- Chronic diarrhea is more common among women than men and those with a body mass index > 30.
- Challenges may exist distinguishing between chronic diarrhea and irritable bowel syndrome diarrheapredominant (IBS-D) as there is overlap in symptoms.
  - Pathogenic mechanisms of chronic diarrhea may be common to that of IBS, including underlying motility disruption.
  - Chronic diarrhea is distinct from IBS-D as it occurs characteristically in the absence of abdominal pain, thus visceral hypersensitivity is less of a feature.

Checklist to guide in-clinic review of your patient with Chronic Diarrhea		
	Confirm absence of alarm features (see algorithm Box 2). If alarm features identified, refer for specialist consultation.	
	Assess Rome IV criteria for IBS – recurrent abdominal pain > 1 day per week in the last three months related to defecation or associated with change of frequency and/or form (appearance) in stool. If present, refer to the <u>IBS pathway</u> .	
	Complete baseline investigations confirming no abnormal results (CBC, electrolytes, ferritin, celiac disease screen, and stool testing for <i>C.difficile</i> and ova and parasites).	
	Address other causes of diarrhea – medical conditions, culprit medications (see <u>Table 1</u> ), alternative diagnoses, and dietary triggers.	

# **EXPANDED DETAILS**

# 1. Suspected chronic diarrhea

A careful history will provide significant insight into the etiology of chronic diarrhea. There are two main categories to consider:

- Functional causes
  - Functional diarrhea without abdominal pain, not associated with inflammation or alteration to the gastrointestinal tract. It is distinct from IBS-D and post-infectious IBS, which is classically associated with pain/abdominal discomfort.

<sup>&</sup>lt;sup>1</sup> Scallan, E., Majowicz, S. E., Hall, G., Banerjee, A., Bowman, C. L., Daly, L., ... & Angulo, F. J. (2005). Prevalence of diarrhea in the community in Australia, Canada, Ireland, and the United States. *International journal of epidemiology*, *34*(2), 454-460.

### Organic causes

 Irritable bowel disease (IBD), celiac disease, microscopic colitis, medication-induced diarrhea, bile acid induced diarrhea (BAD), or other rare causes of diarrhea (e.g., radiation induced).

Chronic diarrhea can also be described as one of, or a combination of, the following pathophysiologic processes:

- Watery Diarrhea:
  - Osmotic
    - The amount of water present in the stool is dependent upon the presence of solutes/effective osmoles (e.g., lactose, fructose).
    - The presence of poorly absorbed solutes (e.g., maldigested sugars) in the bowel inhibit normal water and electrolyte absorption and may lead to diarrhea (presence of higher water content in the stool).
    - Some laxatives (e.g., lactulose, citrate of magnesium) or foods/nutrients (e.g., lactose, sorbitol, and fructose) may not be well absorbed, leading to osmotic diarrhea.
    - When the solute is removed (excluded from the diet), the diarrhea typically resolves.

#### o Secretory

- Caused by excessive electrolyte secretions in the colon, leading to increased fluid.
- One characteristic feature is the persistence of secretion during fasting/removal of food.
- Medications (e.g., antibiotics, proton pump inhibitors (PPIs)), poorly reabsorbed bile acids or fatty acids in the colon, and microscopic colitis are possible causes; and rarely, hormone-producing tumors, excessive prostaglandin production, and other intestinal diseases (e.g., IBD and acquired immune deficiency syndrome (AIDS)).

#### • Inflammatory Diarrhea

- The presence of blood and mucous in the stool can occur from inflammation and this may be immune-mediated. This occurs with chronic conditions, including IBD and other rare chronic infections (e.g., amoebiasis, tuberculosis (TB)).
- Mucous can be a normal presence in stool and does not necessarily reflect inflammation. The key difference is the presence of blood. **This is a red flag and necessitates referra**l.

#### • Overflow Diarrhea

- A history of antecedent chronic constipation, particularly in the elderly, necessitates consideration of overflow diarrhea as a source of new onset/ poorly controlled watery stools in this context.
- Plain x-ray imaging of the abdomen to identify fecal loading may be helpful to direct management (see <u>Chronic Constipation pathway</u>).

#### Additional history:

- Medication review
  - o Many medications can cause chronic diarrhea, including over the counter medications (see Table 1).
- Travel history and associated illness (gastroenteritis)
  - IBS associated with prior short-term, self-limited gastroenteritis is common and can lead to longerterm altered bowel habit (post-infectious changes or IBS). This can occur in conjunction with pain (see <u>IBS pathway</u>).
- **Personal or significant family history of immune-mediated disease** (e.g., thyroid disease, IBD, or celiac disease).
- Diet
  - A dietary review can be helpful to identify easily avoidable contributing factors, such as excessive caffeine, dairy products (e.g., high lactose foods, like milk and ice cream), sugar sweetened beverages, gluten/wheat, etc.



# 2. Alarm features

If any of the following alarm features are identified, refer for consultation/endoscopy. Include any and all identified alarm features in the referral to ensure appropriate triage.

- Family history (first-degree relative) of IBD or colorectal cancer
- Onset of symptoms after age 50
- Unintended weight loss (> 5% over 6-12 months)
- Nocturnal symptoms or significant incontinence
- Visible blood in stool (see High Risk Rectal Bleeding Pathway and/or Iron Deficiency Anemia Pathway)
- Iron deficiency anemia (see Iron Primer)

Although alarm features are important to recognize, they have not been shown to be highly predictive of colon cancer.

#### 3. Baseline investigations

- Blood
  - CBC, electrolytes, ferritin
  - C Reactive Protein (CRP): a non-specific marker of inflammation with modest accuracy for detecting inflammation. The sensitivity or false negative rate is approximately 70-75% with limitations as non-specific. If elevated, it can be helpful, but if normal, does not definitively exclude an inflammatory condition. A very low CRP value is, however, reassuring.<sup>2</sup>
  - Celiac disease screen: a highly accurate (sensitivity is ~95%) antibody screen for this immunemediated condition. Ensure diet is gluten inclusive for at least two weeks prior to testing to ensure no false negatives.
- Stool
  - *C. difficile*, stool for ova and parasites
  - In Alberta, the most common parasites are *Giardia, Cryptosporidium,* and *Entamoeba histolytica*, but others may be indicated if there has been travel history. If there is a relevant travel history or other relevant factors, provide this information in the details of the ova and parasites requisition.
  - Note: Tests such as stool leukocytes and fat globules are generally not recommended. Fecal immunochemical testing (FIT) has NOT been validated for investigation of chronic diarrhea-like symptoms. Ordering FIT in this circumstance is inappropriate given the presence of symptoms.
  - Further investigation using fecal calprotectin consider ordering a fecal calprotectin if there is a high clinical suspicion of inflammation.
  - Fecal calprotectin is a stool-based test used to detect a protein released into the gastrointestinal tract from inflammatory cells (neutrophils) when present. Fecal calprotectin may be elevated and useful when there is a high clinical suspicion of IBD.
  - Elevated levels of fecal calprotectin are found in inflammatory bowel disease (Crohn's disease and Ulcerative colitis). However, mid-range levels can also be found in several benign conditions, such as in patients on NSAIDs or PPIs or those with GI infections, celiac disease, and microscopic colitis (see <u>Microscopic Colitis Primer</u>). By contrast, in functional disorders such as IBS, fecal calprotectin levels are normal.<sup>3</sup>
- FCP methods are not standardized, so numerical FCP results tested by DynaLIFE should **NOT** be compared to previous FCP results from the referral laboratory.

Indication for testing	Result	Interpretive Guidance
	<50 µg/g	Normal (no detectable inflammation).

<sup>&</sup>lt;sup>2</sup> Menees, S. B., Powell, C., Kurlander, J., Goel, A., & Chey, W. D. (2015). A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. *American Journal of Gastroenterology*, *110*(3), 444-454.



<sup>&</sup>lt;sup>3</sup> York Teaching Hospital – NHS Foundation Trust & Yorkshire and Humber Academic Health Sciences Network (2016, July) *The York Faecal Calprotection Care Pathway Information for GPs.* <u>https://www.yorkhospitals.nhs.uk/seecmsfile/?id=941</u>

Investigation of patients with GI symptoms*	50-120 µg/g	<b>Indeterminate</b> (If symptoms persist, consider repeating the test in 4-6 weeks).
	>120 µg/g	Elevated (refer for specialist consultation or physician advice).
Monitoring of known IBD patients	>250 µg/g	Result suggests active inflammation.
*For Patient <4 years of age		
High levels of fecal calprotectin are commonly observed in pediatric patients less than 4 years of age. Robust pediatric reference intervals have not been established for this age group.		

# 4. Optimize management of secondary causes

- A detailed medical history and physical examination should be performed at presentation to assess for a multitude of other conditions that mimic functional diarrhea.
- A careful review of medications should be performed to identify ones that may be causing GI side effects. Some common medications include PPIs, acetylsalicylic acid (ASA), NSAIDs, laxatives/antacids, magnesium supplements, metformin, antidepressants, antigout agents, anti-hypertensives, and herbal products (see <u>Table 1</u>).
  - o Optimization of underlying medical conditions, including diabetes and thyroid disorders
  - Discontinue use or reduce dosage of culprit medications
- Ask about a history of cholecystectomy and whether this coincided with onset or worsening of symptoms. Post-cholecystectomy diarrhea, due to BAD, can be treated with cholestyramine.
- Ask about a history of bariatric surgery and whether this coincided with onset or worsening of symptoms.
- Ask about history of COVID-19 infection.
- Assess common dietary triggers excessive intake of sugar sweetened beverages, juice, alcohol, caffeine (e.g., coffee, tea), artificial sweetener (e.g., sorbitol, diet pop), dairy (e.g., high lactose content in milk and ice cream), and gluten/wheat.

System	Class	Common culprits
	Anti-platelets	ASA
	Antiarrhythmics	digoxin, procainamide
Cardiovascular	Antihypertensives	angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARBs)*, beta-blockers
	Cholesterol/lipid-lowering agents	statins
	Antidepressants	selective serotonin reuptake inhibitor (SSRIs)
Central nervous system	Anti-parkinsonian medications	levodopa, pramipexole, entacapone
oyotom	Others	lithium
Endoorino	Oral hypoglycemic agents	metformin, acarbose, GLP-1 receptor agonists
Endocrine	Thyroid replacement	levothyroxine
	Anti-secretory agents / antacids	proton pump inhibitors (PPIs), magnesium-containing antacids
Gastrointestinal	Laxatives	any
	Other	orlistat
Mussulaskalatal	NSAIDs	ASA, ibuprofen, naproxen
Musculoskeletal	Gout therapy	colchicine, allopurinol
	Antibiotics	most**
	Antineoplastic agents	several
Other	Immunosuppressants	mycophenolate, cyclosporine, tacrolimus, sirolimus
	Vitamin supplements	vitamin C - doses over the upper limit of 2000 mg/day magnesium - doses over the upper limit of elemental Mg 350 mg/day

Table 1: Common medications that may cause diarrhea.

		potassium chloride
	Herbal supplements	
*0		

\*Olmesartan has been associated with sprue-like enteropathy

\*\*Clindamycin, fluoroquinolones, and 3rd-generation cephalosporins are common causes of C. difficile-associated diarrhea

### 5. General principles for treatment and management of chronic diarrhea

Patients with functional bowel disorders will benefit from lifestyle and dietary modifications. These simple modifications may be all that is required in those with mild or intermittent symptoms where quality of life is not significantly impacted. Connecting patients with resources for diet, exercise, stress reduction, and psychological counseling, where available, may be helpful. Initial assessment should include screening for underlying sleep and/or mood disorders. Patients with mental health issues such as depression and anxiety may have refractory symptoms unless mental health issues are addressed.

Treatment options (non-pharmacological)			
	• Details on variable frequency and form that is part of a normal spectrum of bowel habit.		
Education on normal stool form and bowel movement frequency	<ul> <li>There is marked variation in what is considered a normal bowel habit. In a study of healthy individuals, stool frequency varied from a low of 3 to a high of 21 bowel movements per week as being in the normal range.<sup>4</sup> Similarly, there is some normal variation in stool consistency as measured by the <u>Bristol Stool Chart</u>.</li> <li>If stool habit changes substantially, and persists, further investigations may be needed.</li> </ul>		
Patient reassurance and management of expectations	<ul> <li>A key to long-term, effective management is to provide patients reassurance after their initial diagnosis and offer points of reassessment and reappraisal to establish a therapeutic relationship.</li> <li>Reassessment is recommended if there is a significant increase in diarrhea or signs and symptoms of dehydration.</li> </ul>		
	Referral to a dietitian can be helpful.		
	Eat smaller meals spaced over the day to reduce gastric load.		
Modify diet, remove	• Diets high in lactose, fructose, sugar sweetened beverages and juices, diet beverages, sugar free gum, sorbitol, caffeine, and gluten/wheat can increase symptoms.		
trigger foods, and	Water is the best choice for hydration.		
space small meals throughout the day	<ul> <li>Assess common food triggers. Follow a systematic approach of removing triggers and assessing symptoms before permanent elimination.</li> </ul>		
	• It may be helpful for patients to use the <u>Bowel and Symptom Journal</u> to understand their symptoms, food triggers, and stressors. Use the diary to determine how dietary modifications, psychological, and pharmacological therapies impact their symptoms.		

 $(\frown)$ 

<sup>&</sup>lt;sup>4</sup> Mitsuhashi, S., Ballou, S., Jiang, Z. G., Hirsch, W., Nee, J., Iturrino, J., ... & Lembo, A. (2018). Characterizing normal bowel frequency and consistency in a representative sample of adults in the United States (NHANES). *American Journal of Gastroenterology*, *113*(1), 115-123.

	• <b>Total fibre:</b> Adults are recommended to consume 14 g/1000 kcal of fibre per day. Suggest about 21-38 g/day for most adults.
	Two types of fibre:
	<ul> <li>Insoluble fibre is found in wheat bran, the skin of fruits, and many raw vegetables. It adds bulk to the stool and contributes greatly to daily total fibre requirements. It may not add therapeutic health benefits like soluble fibre.</li> </ul>
	<ul> <li>Soluble fibre is found in psyllium, oats, barley, fruit, and seeds. It absorbs water in the intestine to form a viscous gel that thickens the stool and stimulates peristalsis.</li> </ul>
Fibre and fluids	<ul> <li>There is a dose-response relationship between fibre plus fluid intake and stool output. This is important to quantify, as patients whose fibre and fluid intake is inadequate are most likely to benefit from this intervention. Fibre acts as a sponge, so it is important to <b>combine</b> fluid and fibre. Increased fluid intake on its own will only result in increased urination.</li> </ul>
	Soluble fibre supplementation:
	<ul> <li>May provide symptom relief for patients with IBD, IBS, constipation, and diarrhea. The therapeutic goal is 5-10 g/day of soluble fibre from foods and supplements including:</li> </ul>
	<ul> <li>1 tbsp. psyllium husk or powder supplement - 3.0 grams</li> </ul>
	<ul> <li>2 tbsp. ground flaxseed - 1.8 grams</li> </ul>
	<ul> <li>½ cup kidney beans - 2.8 grams</li> </ul>
	<ul> <li>1 pear - 2.2 grams</li> </ul>
	General care:
	General care:         O Increasing fibre intake may result in negative side-effects that can be minimized or avoided.
	<ul> <li>General care:         <ul> <li>Increasing fibre intake may result in negative side-effects that can be minimized or avoided.</li> <li>Slowly increase fibre to prevent gas, abdominal pain, and bloating. Start with a third of a dose and determine tolerance.</li> </ul> </li> </ul>
Fibre and fluids	<ul> <li>General care: <ul> <li>Increasing fibre intake may result in negative side-effects that can be minimized or avoided.</li> <li>Slowly increase fibre to prevent gas, abdominal pain, and bloating. Start with a third of a dose and determine tolerance.</li> <li>Drink additional fluid (water) to compliment a high fibre diet. Inadequate fluid may lead to constipation, hardening of stool, bloating, and abdominal pain.</li> </ul></li></ul>
Fibre and fluids cont'd	<ul> <li>General care: <ul> <li>Increasing fibre intake may result in negative side-effects that can be minimized or avoided.</li> <li>Slowly increase fibre to prevent gas, abdominal pain, and bloating. Start with a third of a dose and determine tolerance.</li> <li>Drink additional fluid (water) to compliment a high fibre diet. Inadequate fluid may lead to constipation, hardening of stool, bloating, and abdominal pain.</li> <li>Caution soluble fibre intake for people with or at risk of a bowel obstruction or narrowing of the esophagus, stomach, or intestine.</li> </ul> </li> </ul>
Fibre and fluids cont'd	<ul> <li>General care: <ul> <li>Increasing fibre intake may result in negative side-effects that can be minimized or avoided.</li> <li>Slowly increase fibre to prevent gas, abdominal pain, and bloating. Start with a third of a dose and determine tolerance.</li> <li>Drink additional fluid (water) to compliment a high fibre diet. Inadequate fluid may lead to constipation, hardening of stool, bloating, and abdominal pain.</li> <li>Caution soluble fibre intake for people with or at risk of a bowel obstruction or narrowing of the esophagus, stomach, or intestine.</li> <li>Fibre supplements may reduce or delay absorption of certain medications.</li> </ul> </li> </ul>
Fibre and fluids cont'd	<ul> <li>General care:         <ul> <li>Increasing fibre intake may result in negative side-effects that can be minimized or avoided.</li> <li>Slowly increase fibre to prevent gas, abdominal pain, and bloating. Start with a third of a dose and determine tolerance.</li> <li>Drink additional fluid (water) to compliment a high fibre diet. Inadequate fluid may lead to constipation, hardening of stool, bloating, and abdominal pain.</li> <li>Caution soluble fibre intake for people with or at risk of a bowel obstruction or narrowing of the esophagus, stomach, or intestine.</li> <li>Fibre supplements may reduce or delay absorption of certain medications.</li> <li>See Patient Resources section for more information on fibre supplementation.</li> </ul> </li> </ul>
Fibre and fluids cont'd	<ul> <li>General care:         <ul> <li>Increasing fibre intake may result in negative side-effects that can be minimized or avoided.</li> <li>Slowly increase fibre to prevent gas, abdominal pain, and bloating. Start with a third of a dose and determine tolerance.</li> <li>Drink additional fluid (water) to compliment a high fibre diet. Inadequate fluid may lead to constipation, hardening of stool, bloating, and abdominal pain.</li> <li>Caution soluble fibre intake for people with or at risk of a bowel obstruction or narrowing of the esophagus, stomach, or intestine.</li> <li>Fibre supplements may reduce or delay absorption of certain medications.</li> <li>See Patient Resources section for more information on fibre supplementation.</li> </ul> </li> <li>Ensure adequate fluids: 2 L/day for females, 3 L/day for males</li> </ul>
Fibre and fluids cont'd Physical activity	<ul> <li>General care:         <ul> <li>Increasing fibre intake may result in negative side-effects that can be minimized or avoided.</li> <li>Slowly increase fibre to prevent gas, abdominal pain, and bloating. Start with a third of a dose and determine tolerance.</li> <li>Drink additional fluid (water) to compliment a high fibre diet. Inadequate fluid may lead to constipation, hardening of stool, bloating, and abdominal pain.</li> <li>Caution soluble fibre intake for people with or at risk of a bowel obstruction or narrowing of the esophagus, stomach, or intestine.</li> <li>Fibre supplements may reduce or delay absorption of certain medications.</li> <li>See Patient Resources section for more information on fibre supplementation.</li> </ul> </li> <li>Ensure adequate fluids: 2 L/day for females, 3 L/day for males</li> <li>20+ minutes of physical activity/day, aiming for 150 min/week is known to be an effective strategy for stress reduction.</li> </ul>
Fibre and fluids cont'd Physical activity	<ul> <li>General care: <ul> <li>Increasing fibre intake may result in negative side-effects that can be minimized or avoided.</li> <li>Slowly increase fibre to prevent gas, abdominal pain, and bloating. Start with a third of a dose and determine tolerance.</li> <li>Drink additional fluid (water) to compliment a high fibre diet. Inadequate fluid may lead to constipation, hardening of stool, bloating, and abdominal pain.</li> <li>Caution soluble fibre intake for people with or at risk of a bowel obstruction or narrowing of the esophagus, stomach, or intestine.</li> <li>Fibre supplements may reduce or delay absorption of certain medications.</li> <li>See <u>Patient Resources</u> section for more information on fibre supplementation.</li> </ul> </li> <li>Ensure adequate fluids: 2 L/day for females, 3 L/day for males</li> <li>20+ minutes of physical activity/day, aiming for 150 min/week is known to be an effective strategy for stress reduction.</li> <li>See the <u>Canadian 24-Hour Movement Guidelines</u>.</li> </ul>

# 6. Pharmacological options for treating chronic diarrhea

# Treatment options (pharmacological)

The use of pharmaceuticals in functional bowel disorders is generally reserved for those who have not adequately responded to dietary and lifestyle interventions, or in those with moderate or severe symptoms that impair quality of life.

<sup>&</sup>lt;sup>5</sup> DynaMed Plus. (2018, September 10). *Confidence in Practice. Irritable bowel syndrome (IBS)*. <u>https://www-dynamed-com.ahs.idm.oclc.org/</u>

	• Evidence: Effective for improved diarrheal symptoms but has not been shown to consistently improve IBS-D symptoms.
	• Mechanism of action: Through $\mu$ (mu) opioid receptor agonist, thus decreasing GI motility.
Loperamide	• <b>Place in therapy:</b> Effective antidiarrheal for prophylaxis for social situations or travel, however, should not be prescribed for continuous use.
(Imodium <sup>®</sup> )	• Adverse effects: Sedation, nausea, abdominal cramps. <sup>6</sup> Lowest addiction potential of all opioids.
	• Dose: 4 mg initially, followed by 2 mg after each loose bowel movement. Max 16 mg/day.
	• Clinical improvement usually seen within 48 hours, if no clinical improvement after at least 10 days on maximum dose, symptoms unlikely to be controlled by further administration. <sup>7</sup>
	• Evidence: Adjunctive therapy in management of moderate to severe diarrhea.
	<ul> <li>Mechanism of action: Through μ (mu) opioid receptor agonist, thus decreasing GI motility. Atropine is an anticholinergic that further decreases GI motility and discourages abuse.</li> </ul>
Diphenoxylate - Atropine (Lomotil <sup>®</sup> )	• <b>Place in therapy:</b> Less effective than loperamide but may be used for intermittent symptoms for some patients.
	• Adverse effects: Sedation, nausea, abdominal cramps, dry skin, and mucous membranes (from atropine). Some addiction potential. <sup>5</sup>
	• Dose: 5 mg PO initially, then 2.5 mg PO after each loose bowel movement. Max 20 mg/day.
Diphenoxylate -	<ul> <li>The elderly are more susceptible to anticholinergic effects.</li> </ul>
cont'd	<ul> <li>Avoid concomitant use with monoamine oxidase inhibitors as this may precipitate hypertensive crisis.</li> </ul>
	• Evidence: The most studied antidepressant class for treatment of abdominal pain. <sup>8</sup>
	• <b>Mechanism of action:</b> Suggested to be beyond serotonin and norepinephrine, and because of blocking voltage-gated ion channels, opioid receptor activation and potential neuro-immunologic anti-inflammatory effects. <sup>9</sup> Their anticholinergic properties also slow GI transit time.
	• <b>Place in therapy:</b> Recommended for overall symptom improvement in patients with IBS, as well as sleep issues, anxiety, or depression.
	• Adverse effects: Anticholinergic and antihistaminic (drowsiness/insomnia, xerostomia, palpitations, weight gain, constipation, urinary retention). <sup>9</sup>
Triovalia	Use with caution in patients at risk of prolonged QT.
antidepressants	It can take 2-3 months to reach maximum effect.
(TCA)	The lowest effective dose should be used. Reassess therapy after 6-12 months.
	Dose should be gradually reduced if discontinuing.
	Recommended Medications
	<ul> <li>Nortriptyline - 10-25 mg qhs. Increase dose by 10-25 mg every 3-4 weeks (due to delayed onset). May require 25-75 mg/day. Often takes 2-3 months for peak effect. (\$20-60/month).</li> </ul>
	• Amitriptyline - 10-25 mg qhs. Increase dose by 10-25 mg every 3-4 weeks (due to delayed onset). May require 25-75 mg/day. Often takes 2-3 months for peak effect. (\$15-20/month).
	• Desipramine - 25 mg qhs, increase based on response and tolerability. Doses up to 150 mg daily have been evaluated for IBS (~\$25/month).

<sup>&</sup>lt;sup>6</sup> DynaMed. Irritable Bowel Syndrome (IBS). EBSCO Information Services. Accessed June 10, 2021. <u>https://www-dynamed-com.ahs.idm.oclc.org/condition/irritable-bowel-syndrome-ibs</u>



<sup>&</sup>lt;sup>7</sup> DynaMed. Chronic Diarrhea. EBSCO Information Services. Accessed June 15, 2021. Chronic Diarrhea - DynaMed (oclc.org)

<sup>&</sup>lt;sup>8</sup> Törnblom, H., & Drossman, D. A. (2016). Centrally targeted pharmacotherapy for chronic abdominal pain: understanding and management. *Gastrointestinal Pharmacology*, 417-440.

<sup>&</sup>lt;sup>9</sup> Lexicomp, Inc., Lexi-Drugs Online, Hudson, Ohio: UpToDate, Inc; 2013; [cited 27 Apr 2021].

	• Evidence: An empiric trial may be considered for suspected bile acid induced diarrhea (BAD). May result in significant clinical improvement in approximately 25% of people. Binds and removes bile acids in the intestine.		
	<ul> <li>Mechanism of action: Through the formation of a non-absorbable complex with bile acids in the intestine.</li> </ul>		
	<ul> <li>Place in therapy: Use gradual daily dose titration to minimize adverse effects and use at the lowest dose needed to minimize symptoms for BAD.<sup>5</sup></li> </ul>		
	Adverse effects: Nausea, fat-soluble vitamin deficiency with long-term use, constipation.		
Dila a sid	Take other medications 1 hour before or 4-6 hours after.		
sequestrants	<ul> <li>Dose: A 2–4-week titration trial is reasonable to see effects. Intermittent, on-demand use may also be trialed.</li> </ul>		
	<ul> <li>Relief usually occurs within 3 days of initiation of therapy. If no relief occurs, alternative therapy should be initiated.<sup>5</sup></li> </ul>		
	Recommended Medications		
	<ul> <li>Cholestyramine resin - 4 g PO Q12H, take with fluids. (\$30/month). Pouch can be divided into a smaller dose and mixed with water or juice (tomato or orange juice) starting at 2-4 g once/day, titrating to effect.</li> </ul>		
	<ul> <li>Colestipol (Colestid<sup>®</sup>) or Colesevelam (Lodalis<sup>®</sup>) available as tablets if patient is unable to tolerate powder.</li> </ul>		
Second line therapies			
Consider consulting a	GI using Specialist Link, Connect MD, or e-Referral Advice Request for guidance on these treatments.		
	A non-systemically absorbed antibiotic.		
Rifaximin (Zaxine <sup>®</sup> )	<ul> <li>Mechanism of action: Not clearly identified, but may alter the microbiome, thus reducing gas production.</li> </ul>		
· · · /	• <b>Dose:</b> 550 mg 3x/daily for 2 weeks. This is a safe medication but tends to require multiple recurrent courses. There is no long-term safety or efficacy data over 3 courses. (~\$325 month, not covered by public insurers).		

# 7. Consider alternative diagnoses

Microscopic Colitis (see <u>Microscopic Colitis Primer</u>)

# • Irritable Bowel Syndrome-diarrhea predominant (IBS-D)

IBS is a brain-gut disorder characterized by recurrent abdominal pain/discomfort and altered bowel habits (constipation, diarrhea, or both). It is often associated with bloating or abdominal distention. These key symptoms can vary in severity and tend to remit and recur, often affected by dietary exposures and stress. For patients with suspected IBS-D, the Rome IV diagnostic criteria may provide a guide.

**Recurrent abdominal pain**, on average,  $\geq$  1 day per week in the last 3 months, associated with  $\geq$  2 of the following criteria where pain is:

- Related to defecation
- Associated with a change in frequency of stool
- o Associated with a change in form (appearance) of stool
- o Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.

If the patient assessment identifies predominant symptoms of pain and/or bloating, refer to the IBS pathway.

# • Bile acid induced diarrhea (BAD)

Bile acids produced in the liver and stored in the gallbladder are normally secreted into the small bowel in response to a meal, and then reabsorbed in the distal ileum (also known as enterohepatic circulation). Bile acid overproduction or poor/ ineffective ileal reabsorption (bile acid malabsorption/ bile acid diarrhea or

 $(\land)$ 

BAM/BAD) can dysregulate this process. Subsequent unabsorbed bile acids stimulate sodium and water secretion in the colon, increase motility, and stimulate defecation, thereby contributing to chronic diarrhea.<sup>10</sup>

#### There are several subtypes:

- Idiopathic: contributing to 25-35% of patients with chronic diarrhea-predominant IBS-D or chronic functional diarrhea
- Post-cholecystectomy
- Other: secondary to small bowel resection (Crohn's disease) or radiation therapy affecting the ileum

#### Diagnosis and treatment:

Diagnosis may be challenging. Giving an empiric trial of bile acid sequestrants is reasonable, easy, and inexpensive. See <u>Treatment options - Bile acid sequestrants</u>.

#### • Small Intestinal Bacterial Overgrowth (SIBO)

Unlike the colon, a significant number of bacteria do not normally reside in the small bowel. Small intestinal bacterial overgrowth (SIBO) is a condition where dysbiosis or increased bacteria are present proximal to the ileocecal valve and within the small bowel where there is normally less bacteria. SIBO is a **rare** cause of gastrointestinal symptoms.

SIBO should only be considered in patients who have:11

- o Severe diabetic neuropathy
- Advanced scleroderma
- Anatomic alterations such as surgery for Crohn's disease, Crohn's strictures, and/or radiation
- o Immune deficiency (e.g., common variable immunodeficiency)
- Note: The accuracy of the breath test for SIBO is highly variable and may be unreliable. Routine testing for SIBO is not currently recommended.<sup>12,13</sup>
- The use of hydrogen breath testing has been used in the past to make a diagnosis of SIBO. However, the accuracy is not consistent, therefore; should not be ordered in primary care.

Empiric antibiotic treatment for SIBO should only be considered for symptomatic patients with at least one of the above considered risk factors. See <u>Second line therapies - Rifaximin</u>.

#### • Pancreatic exocrine insufficiency (PEI)

The normal functioning pancreas produces enzymes responsible for facilitating macronutrient digestion (enzymatic cleavage) so absorption can occur. Pancreatic insufficiency is not a common cause of chronic diarrhea but may be a contributing component in the context of known pancreatic disease (e.g., chronic pancreatitis, cystic fibrosis, or prior surgical resection of the small bowel or stomach). If you suspect pancreatic insufficiency in someone with pancreatic disease, consider testing stool for fecal elastase (low levels suggest pancreatic insufficiency). Routine use of pancreatic enzymes to support digestion are **not** supported by evidence and are costly.

#### 8. When to refer for consultation and/or endoscopy

- If alarm features are identified
- If investigation reveals a positive celiac disease screen
- If the fecal calprotectin result is > 120 µg/g



<sup>&</sup>lt;sup>10</sup> Sadowski, D. C., Camilleri, M., Chey, W. D., Leontiadis, G. I., Marshall, J. K., Shaffer, E. A., ... & Walters, J. R. (2020). Canadian association of gastroenterology clinical practice guideline on the management of bile acid diarrhea. *Journal of the Canadian Association of Gastroenterology*, 3(1), e10-e27.

<sup>&</sup>lt;sup>11</sup> Bull-Henry, K. (2020). Continuing Medical Education Questions: February 2020: ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. *American Journal of Gastroenterology*, *115*(2), 164.

<sup>&</sup>lt;sup>12</sup> Farmer, A. D., Wood, E., & Ruffle, J. K. (2020). An approach to the care of patients with irritable bowel syndrome. *CMAJ*, *192*(11), E275-E282.

<sup>&</sup>lt;sup>13</sup> Shah, A., Talley, N. J., Jones, M., Kendall, B. J., Koloski, N., Walker, M. M., ... & Holtmann, G. J. (2020). Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. *American Journal of Gastroenterology*, *115*(2), 190-201.

- If recommended strategies have led to unsatisfactory treatment or management of symptoms
  - o Note: Consider using an advice service before referring
- Colonoscopy may be helpful in patients with chronic diarrhea who have persistent symptoms or limited benefit from usual treatments.
  - The purpose of endoscopic examination is to exclude chronic immune-mediated conditions including Crohn's disease and microscopic colitis.
  - **Note:** Microscopic colitis is generally a benign condition that is most often treated with antidiarrheal or binding agents).
- Provide as much information as possible on the referral form, including identified alarm feature(s), important findings, and treatment/management strategies trialed with the patient.

# Still concerned about your patient?

The primary care physician is typically the provider who is most familiar with their patient's overall health and knows how they tend to present. Changes in normal patterns, or onset of new or worrisome symptoms, may raise suspicion for a potentially serious diagnosis, even when investigations are normal and typical alarm features are not present.

There is evidence to support the importance of the family physician's intuition or "gut feeling" about patient symptoms, especially when the family physician is worried about a sinister cause such as cancer. A meta-analysis examining the predictive value of gut feelings showed that the odds of a patient being diagnosed with cancer, if a GP recorded a gut feeling, were 4.24 times higher than when no gut feeling was recorded.<sup>14</sup>

When a "gut feeling" persists despite normal investigations, and you decide to refer your patient for specialist consultation, document your concerns on the referral with as much detail as possible. Another option is to seek specialist advice (see <u>Advice Options</u>) to convey your concerns.

# PRIMERS

# **Iron Primer**

Evaluation of measures of iron storage can be challenging. Gastrointestinal (occult) blood loss is a common cause of iron deficiency and should be considered as a cause when iron deficiency anemia is present. Menstrual losses should also be considered.

There are two serological tests to best evaluate iron stores (ferritin, transferrin saturation) - neither of which are perfect.

The first step is to evaluate ferritin:

- If the ferritin is below the lower limit of normal (lower limit of normal is 30 µg/L for men and 20 µg/L for women), it is diagnostic of iron deficiency with high specificity (98% specificity).
- Ferritin is an acute phase reactant which may be elevated in the context of acute inflammation and infection. If ferritin is normal or increased, and you suspect it may be acting as an acute phase reactant, order a transferrin saturation test (see below).
  - However, if the ferritin is > 100 μg/L and there is no concurrent significant chronic renal insufficiency, iron deficiency is very unlikely - even in the context of acute inflammation/infection.

The second step is to evaluate transferrin saturation:

- The transferrin saturation is a calculated ratio using serum iron and total iron binding capacity. Serum iron alone does **not** reflect iron stores.
- Low values (< 16%) demonstrate low iron stores in conjunction with a ferritin < 100 μg/L.

In the absence of abnormal iron indices, anemia may be from other causes other than GI (occult) blood loss (e.g., bone marrow sources, thalassemia, and sickle cell anemia).

<sup>&</sup>lt;sup>14</sup> Friedemann Smith, C., Drew, S., Ziebland, S., & Nicholson, B. D. (2020). Understanding the role of General Practitioners' gut feelings in diagnosing cancer in primary care: A systematic review and meta-analysis of existing evidence. *British Journal of General Practice*, 70(698), e612-e621.

# Microscopic Colitis Primer

Microscopic colitis is a benign condition with a median age of onset in the mid-60s, more often in women than men. It is characterized by non-bloody, watery/secretory diarrhea having significant potential impact on quality of life. Atypical presentations can also occur.

- Examination by colonoscopy reveals normal findings, inflammation is present only histologically (on biopsy).
- Medications have been implicated in the pathophysiology. Common offenders include NSAIDs, proton pump inhibitors (PPIs), statins, topiramate, and SSRIs. Consideration should be given to stopping these medications, if possible.
- This condition is non-progressive, and therapy is directed to improving quality of life and stool habit regularity (< 3 stools per day, minimal water content).</li>
- Treatment for microscopic colitis is similar to those used in the treatment of IBS.
  - Increased soluble fibre (psyllium, inulin) can be helpful to regular stool habit in addition to loperamide, as needed.
  - For more significant manifestations (defecation at night, incontinence), corticosteroid therapy may be indicated (e.g., budesonide/Entocort<sup>®</sup> or Cortiment<sup>®</sup> (little to no evidence exists for prednisone).
- Total treatment duration ranges on response from 6-8 weeks to 12 weeks.



# BACKGROUND

# About this Pathway

- Digestive health primary care pathways were originally developed in 2015 as part of the Calgary Zone's Specialist LINK initiative. They were co-developed by the Department of Gastroenterology and the Calgary Zone's specialty integration group, which includes medical leadership and staff from Calgary and area Primary Care Networks, the Department of Family Medicine, and Alberta Health Services.
- The pathways were intended provide evidence-based guidance to support primary care providers in caring for patients with common digestive health conditions within the medical home.
- Based on the successful adoption of the primary care pathways within the Calgary Zone, and their impact on timely access to quality care, in 2017 the Digestive Health Strategic Clinical Network led an initiative to validate the applicability of the pathways for Alberta and to spread availability and foster adoption of the pathways across the province.

# **Authors & Conflict of Interest Declaration**

This pathway was reviewed and revised under the auspices of the Digestive Health Strategic Clinical Network in 2021, by a multi-disciplinary team led by family physicians and gastroenterologists. Names of participating reviewers and their conflict-of-interest declarations are available on request.

# Pathway Feedback and Review Process

Primary care pathways undergo scheduled review every three years, or earlier if there is a clinically significant change in knowledge or practice. The next scheduled review is May 2024; however, we welcome feedback at any time. Click on the Provide Feedback button to provide your feedback.



# **Copyright Information**



This work is licensed under a <u>Creative Commons Attribution-Non-commercial-Share Alike 4.0 International</u> license. You are free to copy, distribute, and adapt the work for non-commercial purposes, as long as you attribute the work to Alberta Health Services and Primary Care Networks and abide by the other license terms. If you alter, transform, or build upon this work, you may distribute the resulting work only under the same, similar, or compatible license. The license does not apply to content for which the Alberta Health Services is not the copyright owner.

# Disclaimer

This pathway represents evidence-based best practice but does not override the individual responsibility of health care professionals to make decisions appropriate to their patients using their own clinical judgment given their patients' specific clinical conditions, in consultation with patients/alternate decision makers. The pathway is not a substitute for clinical judgment or advice of a qualified health care professional. It is expected that all users will seek advice of other appropriately qualified and regulated health care providers with any issues transcending their specific knowledge, scope of regulated practice or professional competence.

# **PROVIDER RESOURCES**

# **Advice Options**

Non-urgent advice is available to support family physicians.

- Gastroenterology advice is available across the province via Alberta Netcare eReferral Advice Request (responses are received within five calendar days). View the <u>Referring Provider – FAQ</u> document for more information.
- Non-urgent telephone advice connects family physicians and specialists in real time via a tele-advice line. Family physicians can request non-urgent advice from a gastroenterologist:
  - In the Calgary Zone at <u>specialistlink.ca</u> or by calling 403-910-2551. This service is available from 8:00 a.m. to 5:00 p.m. Monday to Friday (excluding statutory holidays). Calls are returned within one (1) hour.
  - In the Edmonton and North Zones by calling 1-844-633-2263 or visiting <u>pcnconnectmd.com</u>. This service is available from 9:00 a.m. to 6:00 p.m. Monday to Thursday and from 9:00 a.m. to 4:00 p.m. Friday (excluding statutory holidays and Christmas break). Calls are returned within two (2) business days.

insecurity.pdf

References		
Ma, C., Battat, R., Parker, C. E., Khanna, R., Jairath, V., & Feagan, B. G. (2019). Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease? <i>Expert review of gastroenterology &amp; hepatology</i> , <i>13</i> (4), 319-330.		
Resources		
Poverty: A Clinical Tool for Primary Care Providers (AB)	cep.health/media/uploaded/Poverty_flowAB-2016-Oct-28.pdf	
Nutrition Guideline: Household Food Insecurity	ahs.ca/assets/info/nutrition/if-nfs-ng-household-food-	

# **PATIENT RESOURCES**

# Information

Description	Website
General information on diarrhea (MyHealth.Alberta.ca)	myhealth.alberta.ca/health/pages/conditions.aspx?Hwid=diar4
General information on diarrhea (Canadian Digestive Health Foundation)	cdhf.ca/digestive-disorders/diarrhea/
Diarrhea and Diet (GI Society & Canadian Society of Intestinal Research)	badgut.org/information-centre/health-nutrition/diarrhea-and-diet/
Fibre Facts	ahs.ca/assets/info/nutrition/if-nfs-fibre-facts.pdf
Bowel and Symptom Journal	ahs.ca/assets/info/nutrition/if-nfs-bowel-symptom-journal.pdf
Nutrition Education Material	ahs.ca/NutritionResources
Gut Health Patient Journal (Physician Learning Program)	9c849905-3a37-465a-9612- 7db1b9a0a69c.filesusr.com/ugd/7b74c1_81f1695f08214a66bc3394 62c52cd011.pdf

# Services Available

Description	Website
Services for patients to prevent or to manage chronic conditions (Alberta Healthy Living Program - AHS)	ahs.ca/ahlp
Supports for working towards healthy lifestyle goals and weight management (Weight Management – AHS)	ahs.ca/info/Page15163.aspx
Referral to a Registered Dietitian	<ul> <li>Visit<u>Alberta Referral Directory</u> and search for nutrition counselling.</li> <li>To learn more about programs and services offered in your zone, visit <u>Nutrition Services</u>.</li> <li><u>Health Link</u> has Registered Dietitians available to answer nutrition questions. If a patient has nutrition-related questions, they can call 8-1-1 and ask to talk to a Dietitian.</li> <li>Patients can also complete the Health Link Dietitian <u>Self-Referral Form</u>.</li> </ul>

# **PATIENT PATHWAY**

Chronic diarrhea patient pathway

